| Literature DB >> 36176340 |
Yucheng Ma1, Lede Lin1, Zhumei Luo2, Tao Jin1.
Abstract
Purpose: To evaluate the superior calyceal access's performance and safety in relation to other calyceal access during percutaneous nephrolithotomy (PCNL).Entities:
Keywords: complication; meta-analysis; percutaneous nephrolithotomy; stone clearance; superior calyceal access
Year: 2022 PMID: 36176340 PMCID: PMC9513144 DOI: 10.3389/fsurg.2022.930159
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Study searching and screening flow chart.
Characteristics of included studies.
| Author | Year | study design | Study location | Total Participants | Superior calyceal access participant | Other calyceal location | Other calyceal access participants | Age of included patients | kidney stone location | Patient position | PCNL type | Guided method | Stone clearance definition (residual size) | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monish Aron | 2004 | PCS | India | 102 | 69 | Inferior calyceal | 33 | Not reported | Inferior calyceal calculi | Not reported | Standard PCNL | NR | Residual calculi at 1 day (2 mm) | 7 |
| Nelson Rodrigues Netto | 2004 | RCS | Brazil | 86 | 16 | Inferior and middle calyceal | 70 | 34 ± 11.88 for superior access; | Staghorn stones | Prone position | Standard PCNL | Ultrasonography | Residual calculi at 1 day (5 mm) | 6 |
| Ahmet Tefekli | 2012 | PCS | Multi center | 3515 | 403 | Inferior calyceal | 3112 | Not reported | Upper calyx, middle calyx, lower calyx, renal pelvis, and multiple stones | Both supine or prone position applied | Standard PCNL | X-ray fluoroscopy or ultrasonography | Residual calculi at 1 month (NR) | 8 |
| Rohit Singh | 2014 | PCS | India | 94 | 43 | Inferior calyceal | 51 | 39.84 ± 10.42 for superior access; | Staghorn stones | Prone position | Standard PCNL | X-ray fluoroscopy | Auxiliary procedures needed | 7 |
| Vishwajeet Singh | 2015 | RCT | India | 100 | 50 | Inferior calyceal | 50 | 38.6 ± 6.5for superior access; | Inferior | Prone position | Standard PCNL | X-ray fluoroscopy | Auxiliary procedures needed | / |
| Faruk Özgör | 2015 | RCS | Turkey | 360 | 42 | Inferior and middle calyceal | 318 | 46.7 ± 14.1for superior access; | Isolated lower, middle, | Prone position | Standard PCNL | X-ray fluoroscopy | Residual calculi at 3 month (4 mm) | 7 |
| Yan Song | 2016 | RCS | China | 153 | 45 | Inferior and middle calyceal | 108 | 48.9 ± 9.2 for superior access; | Single pelvic stone. | Not reported | Standard PCNL | Ultrasonography | Residual calculi at 1 day (5 mm) | 7 |
| Kyle A. Blum | 2018 | PCS | USA | 76 | 17 | Inferior calyceal | 59 | 55.22 ± 15.31 for superior access; | Staghorn stones | Prone position | Standard PCNL | X-ray fluoroscopy | Residual calculi at 1 month (NR) | 6 |
| Liquan Zhou | 2018 | RCS | China | 1438 | 415 | Inferior and middle calyceal | 1023 | 46.32 ± 10.31 for superior access; | Upper calyx, middle calyx, lower calyx, renal pelvis, and multiple stones | Prone position | Standard PCNL | X-ray fluoroscopy or ultrasonography | Residual calculi at 3 days (4 mm) | 6 |
| Sedat Oner | 2018 | PCS | Turkey | 77 | 10 | Inferior and middle calyceal | 67 | 9.58 ± 3.88 for superior access; | Upper calyx, middle calyx, lower calyx, renal pelvis, and multiple stones | Prone position | Standard PCNL | X-ray fluoroscopy | Residual calculi at 1 day (4 mm) | 7 |
| Ricardo M. O. Soares | 2019 | RCS | USA | 329 | 227 | Inferior and middle calyceal | 102 | Not reported | Not reported | Prone position | Standard PCNL | X-ray fluoroscopy | Residual calculi at 1 day (3 mm) | 7 |
| Patrick L. Vande Lune | 2019 | RCS | USA | 591 | 424 | Inferior and middle calyceal | 167 | Not reported | Upper calyx, middle calyx, lower calyx, renal pelvis, and multiple stones | Not reported | Standard PCNL | X-ray fluoroscopy | Residual calculi at 1 day (NR) | 7 |
| Charles U. Nottingham | 2020 | PCS | USA | 767 | 112 | Inferior and middle calyceal | 655 | 58.35 ± 14.27 for superior access; | Upper calyx, middle calyx, lower calyx, renal pelvis, and multiple stones | Prone position (mostly prone position, indicated that there might be some other position such as supine) | Standard PCNL | X-ray fluoroscopy | Residual calculi at 1 day (NR) | 8 |
| M. Amaresh | 2021 | PCS | India | 126 | 63 | Inferior calyceal | 63 | 45.81 ± 3.72 for superior access; | Inferior | Prone position | Standard and mini PCNL | X-ray fluoroscopy | Residual calculi at 1 month (4 mm) | 7 |
| Suxi Huang | 2021 | RCS | China | 258 | 206 | Inferior calyceal | 52 | 43.34 ± 8.30 for superior access; | Inferior calyceal calculi | Prone position | Standard PCNL | ultrasonography | Residual calculi at 3 day (4 mm) | 8 |
| Yu Zhang | 2021 | RCS | China | 379 | 146 | Inferior and middle calyceal | 233 | 52.22 ± 11.33 for superior access; | Staghorn calculi | Prone position | Standard PCNL | X-ray fluoroscopy | Residual calculi at 1 day (4 mm) | 6 |
PCNL, percutaneous nephrolithotomy; NR, not reported; PCS, prospective cohort study; RCS, retrospective cohort study; RCT, randomized controlled trial; NOS, Newcastle-Ottawa Scale.
Figure 2Forest plots of meta-analysis. (A) Stone clearance comparison between superior calyceal access and other calyceal access. (B) Additional puncture rate comparison between superior calyceal access and other calyceal access. (C) Complication comparison between superior calyceal access and other calyceal access.
Figure 3Forest plots of meta-analysis. (A) Operation time comparison between superior calyceal access and other calyceal access. (B) Hospital stays comparison between superior calyceal access and other calyceal access.
Figure 4Funnel plots of meta-analysis. (A) Funnel plot for stone clearance comparison. (B) Funnel plot for complication comparison. (C) Funnel plot for operation time comparison. (D) Funnel plot for hospital stay comparison. (E) Funnel plot for additional puncture comparison.
Subgroup analyses of additional puncture comparison.
| Subgroup | Pooled OR for additional puncture | Heterogeneity | ||
|---|---|---|---|---|
| OR (95% CI) |
| |||
| Recent 5-year study (yes) | ||||
| Yes | 0.35 (0.24–0.52) | <0.001 | 23.5% | 0.271 |
| No | 0.34 (0.13–0.89) | 0.028 | 22.4% | 0.256 |
| Study design | ||||
| RCT | 0.08 (0.00–1.52) | 0.093 | — | — |
| PCS | 0.51 (0.24–1.09) | 0.082 | 0.0% | 0.446 |
| RCS | 0.32 (0.21–0.49) | <0.001 | — | — |
| Study location | ||||
| Asia | 0.30 (0.13–0.73) | 0.008 | 0.0% | 0.441 |
| America | 0.36 (0.24–0.55) | <0.001 | 56.3% | 0.130 |
| Sample size > 200 | ||||
| Yes | 0.32 (0.21–0.49) | 0.018 | — | — |
| No | 0.42 (0.21–0.86) | <0.001 | 5.7% | 0.365 |
| Other access type | ||||
| Inferior calyceal access | 0.42 (0.21–0.86) | <0.001 | 5.7% | 0.365 |
| Inferior and middle calyceal access | 0.32 (0.210.49) | 0.018 | ||
| Types of kidney stones | ||||
| Staghorn calculi | 0.62 (0.27–1.40) | 0.246 | 0.0% | 0.446 |
| Not specified | 0.30 (0.20–0.45) | <0.001 | 0.0% | 0.588 |
| Types of PCNL | ||||
| Standard PCNL | 0.36 (0.25–0.52) | <0.001 | 14.9% | 0.318 |
| Standard PCNL + mini PCNL | 0.19 (0.02–1.65) | 0.131 | — | — |
| Guide method: x-ray fluoroscopy | 0.35 (0.24–0.51) | <0.001 | 0.0% | 0.424 |
OR, odds ratio; CI, confidence interval; RCT, randomized controlled trial; PCS, prospective cohort study; RCS, retrospective cohort study; PCNL, Percutaneous nephrolithotomy.
Subgroup analyses of failed stone clearance.
| Subgroup | Pooled OR for failed stone clearance | Heterogeneity | ||
|---|---|---|---|---|
| OR (95% CI) |
| |||
| Recent 5-year study (yes) | ||||
| Yes | 0.63 (0.45–0.87) | 0.006 | 61.7% | 0.005 |
| No | 0.63 (0.31–1.27) | 0.197 | 67.0% | 0.010 |
| Study design | ||||
| RCT | 0.10 (0.01–1.95) | 0.129 | — | — |
| PCS | 0.70 (0.41–0.18) | 0.179 | 67.5% | 0.005 |
| RCS | 0.62 (0.44–0.88) | 0.007 | 60.6% | 0.013 |
| Study location | ||||
| Asia | 0.47 (0.34–0.66) | <0.001 | 34.8% | 0.129 |
| America | 0.90 (0.70–1.16) | 0.411 | 0.0% | 0.504 |
| Sample size >200 | ||||
| Yes | 0.73 (0.50–1.06) | 0.094 | 82.4% | <0.001 |
| No | 0.46 (0.28–0.75) | 0.002 | 0.0% | 0.497 |
| Other access type | ||||
| Inferior calyceal access | 0.45 (0.19–1.04) | 0.063 | 83.8% | <0.001 |
| Inferior and middle calyceal access | 0.74 (0.58–0.93) | 0.010 | 28.4% | 0.192 |
| Types of kidney stones | ||||
| Pelvic calculi | 0.79 (0.20–3.05) | 0.727 | — | — |
| Staghorn calculi | 0.72 (0.50–1.05) | 0.086 | 0.0% | 0.645 |
| Inferior calyceal calculi | 0.26 (0.15–0.45) | <0.001 | 0.0% | 0.728 |
| Not specified | 0.75 (0.50–1.10) | 0.143 | 74.7% | <0.001 |
| Types of PCNL | ||||
| Standard PCNL | 0.67 (0.49–0.92) | 0.012 | 71.3% | <0.001 |
| Standard PCNL + mini PCNL | 0.19 (0.04–0.95) | 0.043 | — | — |
| Guide method | ||||
| X-ray fluoroscopy | 0.78 (0.61–1.01) | 0.056 | 19.4% | 0.264 |
| Ultrasonography | 0.38 (0.18–0.83) | 0.015 | 30.4% | 0.238 |
| X-ray fluoroscopy or ultrasonography | 0.82 (0.30–2.25) | 0.706 | 95.4% | <0.001 |
| NR | 0.30 (0.11–0.82) | 0.019 | — | — |
| Clearance definition | ||||
| Additional treatment needed | 0.36 (0.12–1.03) | 0.056 | 0.0% | 0.367 |
| Residuals identified by imaging | 0.67 (0.48–0.93) | 0.015 | 73.3% | <0.001 |
OR, odds ratio; CI, confidence interval; RCT, randomized controlled trial; PCS, prospective cohort study; RCS, retrospective cohort study; PCNL, percutaneous nephrolithotomy; NR, not reported.
Subgroup analyses of complication.
| Subgroup | Pooled OR for complication | Heterogeneity | ||
|---|---|---|---|---|
| OR (95% CI) |
| |||
| Recent 5-year study (yes) | ||||
| Yes | 1.00 (0.62–1.60) | 0.983 | 78.8% | <0.001 |
| No | 1.38 (0.86–2.20) | 0.184 | 53.6% | 0.056 |
| Study design | ||||
| RCT | 0.72 (0.23–2.24) | 0.566 | — | — |
| PCS | 1.09 (0.62–1.89) | 0.771 | 55.7% | 0.035 |
| RCS | 1.16 (0.69–1.94) | 0.581 | 84.7% | <0.001 |
| Study location | ||||
| Asia | 0.84 (0.51–1.39) | 0.488 | 76.7% | <0.001 |
| America | 1.65 (0.87–3.13) | 0.125 | 64.2% | 0.025 |
| Sample size >200 | ||||
| Yes | 1.16 (0.74–1.83) | 0.513 | 87.0% | <0.001 |
| No | 0.97 (0.61–1.56) | 0.914 | 16.3% | 0.302 |
| Other access type | ||||
| Inferior calyceal access | 1.38 (0.98–1.93) | 0.601 | 86.2% | <0.001 |
| Inferior and middle calyceal access | 0.79 (0.33–1.91) | 0.066 | 60.2% | 0.010 |
| Types of kidney stones | ||||
| Pelvic calculi | 1.24 (0.49–3.15) | 0.647 | — | — |
| Staghorn calculi | 1.35 (0.71–2.58) | 0.361 | 45.9% | 0.136 |
| Inferior calyceal calculi | 0.30 (0.06–1.54) | 0.150 | 80.5% | 0.023 |
| Not specified | 1.32 (0.92–1.91) | 0.133 | 71.9% | <0.001 |
| Types of PCNL | ||||
| Standard PCNL | 1.15 (0.81–1.63) | 0.432 | 77.1% | <0.001 |
| Standard PCNL + mini PCNL | 0.40 (0.10–1.62) | 0.200 | — | — |
| Guide method | ||||
| X-ray fluoroscopy | 1.37 (0.90–2.10) | 0.148 | 61.9% | 0.005 |
| Ultrasonography | 0.57 (0.12–2.75) | 0.486 | 86.9% | <0.001 |
| X-ray fluoroscopy or ultrasonography | 1.23 (0.68–2.23) | 0.487 | 90.1% | 0.001 |
| NR | 0.73 (0.22–2.45) | 0.615 | — | — |
OR, odds ratio; CI, confidence interval; RCT, randomized controlled trial; PCS, prospective cohort study; RCS, retrospective cohort study; PCNL, percutaneous nephrolithotomy; NR, not reported.
Figure 5Funnel plot for trim-and-fill analysis. Hollow circle means added simulated studies.